Abstract
Statins, ezetimibe, and bile acid-binding resins can be used individually or in combination for lowering low-density lipoprotein cholesterol (LDL-C) levels. Statins are the most potent drugs for lowering LDL-C and are well tolerated in most patients. The addition of a bile acid sequestrant or ezetimibe to a statin produces additional LDL-C reduction allowing many patients to reach LDL-C targets. This article discusses the efficacy and safety of available statins, bile acid sequestrants, and ezetimibe in the treatment of hyperlipidemia.
MeSH terms
-
Animals
-
Anticholesteremic Agents / administration & dosage
-
Anticholesteremic Agents / adverse effects
-
Anticholesteremic Agents / pharmacology
-
Anticholesteremic Agents / therapeutic use*
-
Azetidines / adverse effects
-
Azetidines / therapeutic use*
-
Bile Acids and Salts / metabolism*
-
Cholesterol, LDL / blood*
-
Drug Therapy, Combination
-
Ezetimibe
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hyperlipidemias / blood
-
Hyperlipidemias / drug therapy
-
Hypolipidemic Agents / adverse effects
-
Hypolipidemic Agents / therapeutic use*
-
Lipoproteins, LDL / blood*
-
Niacin / therapeutic use
Substances
-
Anticholesteremic Agents
-
Azetidines
-
Bile Acids and Salts
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
Lipoproteins, LDL
-
Niacin
-
Ezetimibe